Analysis ‘may help to better understand, although not change’ trial’s neutral primary results, investigator says
Sacubitril/valsartan was superior to ramipril among high-risk survivors of acute myocardial infarction (MI), according to a new post hoc win-ratio analysis of the PARADISE-MI randomized trial, even though the trial’s primary results showed no difference between the medications in cardiovascular death or incident heart failure.